---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-000900"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:08:43.186880+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anebulo: Phase 2 data show ANEB-001 reduces THC effects; cash $16M runway into 2024

## Summary
- Preliminary data: single 10 mg ANEB-001 reversed key psychotropic effects of 30 mg THC, including feeling high and body sway.
- Delayed dosing of ANEB-001 (1 hour after THC) rapidly reversed pre-existing effects.
- Full PK, PD, and safety data expected by end of 1Q2023; FDA End of Phase 2A meeting targeted H1 2023.
- Cash of $16M as of Dec 31, 2022 provides runway into 2024.
- No serious adverse events; 134 subjects enrolled in Parts A and B.

## SEC filing metadata
- accession: 0001493152-23-000900
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315223000900/0001493152-23-000900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315223000900/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-000900
- JSON: https://secwatch.observer/filing/0001493152-23-000900.json
- Plain text: https://secwatch.observer/filing/0001493152-23-000900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.